表紙
市場調查報告書

生物可吸收支架:醫療設備的開發平台評估

Bioabsorbable Stents (BAS) - Medical Devices Pipeline Assessment, 2019

出版商 GlobalData 商品編碼 347100
出版日期 內容資訊 英文 119 Pages
訂單完成後即時交付
價格
Back to Top
生物可吸收支架:醫療設備的開發平台評估 Bioabsorbable Stents (BAS) - Medical Devices Pipeline Assessment, 2019
出版日期: 2019年12月20日內容資訊: 英文 119 Pages
簡介

本報告提供生物可吸收支架的開發中產品調查分析,以各開發階段比較分析為焦點,提供開發中產品的開發中主要企業,進行中的臨床試驗相關資訊等系統性資訊。

第1章 目錄

第2章 簡介

  • 生物可吸收支架概要

第3章 開發中的產品

  • 生物可吸收支架 - 開發中產品:各開發階段
  • 生物可吸收支架 - 開發中產品:各地區
  • 生物可吸收支架 - 開發中產品:各法規
  • 生物可吸收支架 - 開發中產品:各核准預定日
  • 生物可吸收支架 - 進行中的臨床試驗

第4章 生物可吸收支架 - 正在開發的開發中產品:各企業

  • 生物可吸收支架企業 - 開發中產品:各開發階段
  • 生物可吸收支架 - 開發中產品:各開發階段

第5章 生物可吸收支架企業與產品概要

  • Abbott Vascular Inc.
  • AlviMedica Medical Technologies Inc.
  • Amaranth Medical, Inc.
  • Arterius Ltd
  • Biosensors International Group, Ltd.
  • Biotronik SE & Co. KG
  • Boston Scientific Corporation
  • Cardionovum GmbH
  • Elixir Medical Corporation
  • HangZhou HuaAn Biotechnology Co., Ltd.
  • Icon Interventional Systems, Inc.
  • 日本支架科技
  • Lepu Medical Technology (Beijing) Co., Ltd.
  • Medlogics Device Corporation
  • Meril Life Sciences Pvt. Ltd.
  • MicroPort Scientific Corporation
  • NanoCoeur, Inc.
  • Northwestern University
  • OrbusNeich
  • REVA Medical, Inc.
  • S3V Vascular Technologies
  • Shanghai MicroPort Medical (Group) Co., Ltd.
  • Tepha, Inc.
  • Terumo Corporation
  • Xenogenics Corporation
  • Zorion Medical

第6章 生物可吸收支架 - 最近的趨勢

第7章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDME0884EPD

GlobalData's Medical Devices sector report, "Bioabsorbable Stents (BAS) - Medical Devices Pipeline Assessment, 2019" provides an overview of Bioabsorbable Stents (BAS) currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Bioabsorbable Stents (BAS) pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Bioabsorbable Stents (BAS) under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Bioabsorbable Stents (BAS) and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Bioabsorbable Stents (BAS) under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

  • 1.1 List of Tables 5
  • 1.2 List of Figures 9

2 Introduction 10

  • 2.1 Bioabsorbable Stents (BAS) Overview 10

3 Products under Development 11

  • 3.1 Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development 11
  • 3.2 Bioabsorbable Stents (BAS) - Pipeline Products by Territory 12
  • 3.3 Bioabsorbable Stents (BAS) - Pipeline Products by Regulatory Path 13
  • 3.4 Bioabsorbable Stents (BAS) - Pipeline Products by Estimated Approval Date 14
  • 3.5 Bioabsorbable Stents (BAS) - Ongoing Clinical Trials 15

4 Bioabsorbable Stents (BAS) - Pipeline Products under Development by Companies 16

  • 4.1 Bioabsorbable Stents (BAS) Companies - Pipeline Products by Stage of Development 16
  • 4.2 Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development 18

5 Bioabsorbable Stents (BAS) Companies and Product Overview 20

  • 5.1 Abbott Vascular Inc Company Overview 20
    • 5.1.1 Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview 20
  • 5.2 Amaranth Medical Inc Company Overview 21
    • 5.2.1 Amaranth Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 21
  • 5.3 Arterius Ltd Company Overview 30
    • 5.3.1 Arterius Ltd Pipeline Products & Ongoing Clinical Trials Overview 30
  • 5.4 Biosensors International Group Ltd Company Overview 31
    • 5.4.1 Biosensors International Group Ltd Pipeline Products & Ongoing Clinical Trials Overview 31
  • 5.5 Biosten, LLC Company Overview 32
    • 5.5.1 Biosten, LLC Pipeline Products & Ongoing Clinical Trials Overview 32
  • 5.6 Biotronik AG Company Overview 33
    • 5.6.1 Biotronik AG Pipeline Products & Ongoing Clinical Trials Overview 33
  • 5.7 Biotronik SE & Co KG Company Overview 43
    • 5.7.1 Biotronik SE & Co KG Pipeline Products & Ongoing Clinical Trials Overview 43
  • 5.8 Boston Scientific Corp Company Overview 44
    • 5.8.1 Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 44
  • 5.9 Cardionovum GmbH Company Overview 49
    • 5.9.1 Cardionovum GmbH Pipeline Products & Ongoing Clinical Trials Overview 49
  • 5.10 Cordis Corp Company Overview 50
    • 5.10.1 Cordis Corp Pipeline Products & Ongoing Clinical Trials Overview 50
  • 5.11 HangZhou HuaAn Biotechnology Co., Ltd. Company Overview 51
    • 5.11.1 HangZhou HuaAn Biotechnology Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 51
  • 5.12 Icon Interventional Systems, Inc. Company Overview 52
    • 5.12.1 Icon Interventional Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview 52
  • 5.13 Japan Stent Technology Co., Ltd. Company Overview 53
    • 5.13.1 Japan Stent Technology Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 53
  • 5.14 Kyoto Medical Planning Co Ltd Company Overview 54
    • 5.14.1 Kyoto Medical Planning Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 54
  • 5.15 Lifetech Scientific (Shenzhen) Co Ltd Company Overview 55
    • 5.15.1 Lifetech Scientific (Shenzhen) Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 55
  • 5.16 Manli Cardiology Ltd Company Overview 58
    • 5.16.1 Manli Cardiology Ltd Pipeline Products & Ongoing Clinical Trials Overview 58
  • 5.17 Micell Technologies Inc Company Overview 59
    • 5.17.1 Micell Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 59
  • 5.18 Michigan Technological University Company Overview 64
    • 5.18.1 Michigan Technological University Pipeline Products & Ongoing Clinical Trials Overview 64
  • 5.19 MicroPort Scientific Corp Company Overview 65
    • 5.19.1 MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 65
  • 5.20 Minvasys SAS Company Overview 69
    • 5.20.1 Minvasys SAS Pipeline Products & Ongoing Clinical Trials Overview 69
  • 5.21 MIV Therapeutics Inc Company Overview 70
    • 5.21.1 MIV Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 70
  • 5.22 NanoCoeur, Inc. Company Overview 72
    • 5.22.1 NanoCoeur, Inc. Pipeline Products & Ongoing Clinical Trials Overview 72
  • 5.23 North Carolina State University Company Overview 73
    • 5.23.1 North Carolina State University Pipeline Products & Ongoing Clinical Trials Overview 73
  • 5.24 Northwestern University Company Overview 74
    • 5.24.1 Northwestern University Pipeline Products & Ongoing Clinical Trials Overview 74
  • 5.25 OrbusNeich Company Overview 75
    • 5.25.1 OrbusNeich Pipeline Products & Ongoing Clinical Trials Overview 75
  • 5.26 Pediastent LLC Company Overview 77
    • 5.26.1 Pediastent LLC Pipeline Products & Ongoing Clinical Trials Overview 77
  • 5.27 QualiMed Innovative Medizinprodukte GmbH Company Overview 78
    • 5.27.1 QualiMed Innovative Medizinprodukte GmbH Pipeline Products & Ongoing Clinical Trials Overview 78
  • 5.28 REVA Medical Inc Company Overview 79
    • 5.28.1 REVA Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 79
  • 5.29 S3V Vascular Technologies Company Overview 84
    • 5.29.1 S3V Vascular Technologies Pipeline Products & Ongoing Clinical Trials Overview 84
  • 5.30 Tepha Inc Company Overview 85
    • 5.30.1 Tepha Inc Pipeline Products & Ongoing Clinical Trials Overview 85
  • 5.31 University of Alabama at Birmingham Company Overview 86
    • 5.31.1 University of Alabama at Birmingham Pipeline Products & Ongoing Clinical Trials Overview 86
  • 5.32 University of Florida Company Overview 87
    • 5.32.1 University of Florida Pipeline Products & Ongoing Clinical Trials Overview 87
  • 5.33 University of Strathclyde Company Overview 88
    • 5.33.1 University of Strathclyde Pipeline Products & Ongoing Clinical Trials Overview 88
  • 5.34 VasoTech Inc. Company Overview 89
    • 5.34.1 VasoTech Inc. Pipeline Products & Ongoing Clinical Trials Overview 89
  • 5.35 Xenogenics Corporation Company Overview 90
    • 5.35.1 Xenogenics Corporation Pipeline Products & Ongoing Clinical Trials Overview 90

6 Bioabsorbable Stents (BAS)- Recent Developments 93

  • 6.1 Nov 06, 2019: Final five unpublished late-breaking clinical trial results announced at VIVA19 93
  • 6.2 Oct 23, 2019: Boston Scientific announces results for third quarter 2019 95
  • 6.3 Sep 20, 2019: Terumo to increase production capacity for alliance business 97
  • 6.4 Aug 29, 2019: MicroPort announces interim results for the six months ended June 30, 2019 98
  • 6.5 Aug 28, 2019: Boston Scientific Celebrates 15th Anniversary in Costa Rica 100

7 Appendix 116

  • 7.1 Methodology 116
  • 7.2 About GlobalData 119
  • 7.3 Contact Us 119
  • 7.4 Disclaimer 119

List of Tables

  • Table 1: Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development
  • Table 2: Bioabsorbable Stents (BAS) - Pipeline Products by Territory
  • Table 3: Bioabsorbable Stents (BAS) - Pipeline Products by Regulatory Path
  • Table 4: Bioabsorbable Stents (BAS) - Pipeline Products by Estimated Approval Date
  • Table 5: Bioabsorbable Stents (BAS) - Ongoing Clinical Trials
  • Table 6: Bioabsorbable Stents (BAS) Companies - Pipeline Products by Stage of Development
  • Table 7: Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development
  • Table 8: Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 9: Second Generation Bioresorbable Vascular Scaffold - Product Status
  • Table 10: Second Generation Bioresorbable Vascular Scaffold - Product Description
  • Table 11: Amaranth Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 12: 80-micron MAGNITUDE Bioresorbable Scaffold - Product Status
  • Table 13: 80-micron MAGNITUDE Bioresorbable Scaffold - Product Description
  • Table 14: APTITUDE Sirolimus-Eluting Bioresorbable Scaffold - Product Status
  • Table 15: APTITUDE Sirolimus-Eluting Bioresorbable Scaffold - Product Description
  • Table 16: DEFIANCE Scaffold - Product Status
  • Table 17: DEFIANCE Scaffold - Product Description
  • Table 18: FORTITUDE Scaffold - Product Status
  • Table 19: FORTITUDE Scaffold - Product Description
  • Table 20: MAGNITUDE Sirolimus-Eluting Bioresorbable Scaffold - Product Status
  • Table 21: MAGNITUDE Sirolimus-Eluting Bioresorbable Scaffold - Product Description
  • Table 22: Second Generation FORTITUDE Scaffold - Product Status
  • Table 23: Second Generation FORTITUDE Scaffold - Product Description
  • Table 24: Amaranth Medical Inc - Ongoing Clinical Trials Overview
  • Table 25: FORTITUDE Scaffold - Amaranth Endovascular Study of a Drug-eluting Bioresorbable Coronary Scaffold
  • Table 26: FORTITUDE Scaffold - Restoring Endoluminal Narrowing Using Bioresorbable Scaffolds - European Trial
  • Table 27: APTITUDE Sirolimus-Eluting Bioresorbable Scaffold - Restoring Endoluminal Narrowing Using Bioresorbable Scaffolds - Extended Trial II
  • Table 28: MAGNITUDE Sirolimus-Eluting Bioresorbable Scaffold - Restoring Endoluminal Narrowing Using Bioresorbable Scaffolds - Extended Trial III
  • Table 29: Arterius Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 30: Arteriosorb Absorbable Drug-Eluting Scaffold - Product Status
  • Table 31: Arteriosorb Absorbable Drug-Eluting Scaffold - Product Description
  • Table 32: Biosensors International Group Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 33: Sparrow Drug Eluting Stent System - Product Status
  • Table 34: Sparrow Drug Eluting Stent System - Product Description
  • Table 35: Biosten, LLC Pipeline Products & Ongoing Clinical Trials Overview
  • Table 36: Biodegradable Endovascular Implant - Product Status
  • Table 37: Biodegradable Endovascular Implant - Product Description
  • Table 38: Biotronik AG Pipeline Products & Ongoing Clinical Trials Overview
  • Table 39: Magmaris Bioresorbable Magnesium Scaffold - Product Status
  • Table 40: Magmaris Bioresorbable Magnesium Scaffold - Product Description
  • Table 41: Magmaris Bioresorbable Magnesium Scaffold - 3rd Generation - Product Status
  • Table 42: Magmaris Bioresorbable Magnesium Scaffold - 3rd Generation - Product Description
  • Table 43: Biotronik AG - Ongoing Clinical Trials Overview
  • Table 44: Magmaris Bioresorbable Magnesium Scaffold - A Sirolimus Eluting Bioresorbable Magnesium Stent for Treatment of Coronary Bifurcation Lesions: The BIFSORB Pilot Study II
  • Table 45: Magmaris Bioresorbable Magnesium Scaffold - BIOTRONIK - Safety and Clinical Performance of the Drug Eluting Absorbable Metal Scaffold (DREAMS 2nd Generation) in the Treatment of Subjects with de Novo Lesions in Native Coronary Arteries: BIOSOLVE-II
  • Table 46: Magmaris Bioresorbable Magnesium Scaffold - BIOTRONIKS - Acute Performance of a Drug Eluting Absorbable Metal Scaffold (DREAMS 2G) in Patients with de Novo Lesions in Native Coronary Arteries: BIOSOLVE-III
  • Table 47: Magmaris Bioresorbable Magnesium Scaffold - Biotroniks - Safety and Performance in de Novo Lesion of Native Coronary Arteries with Magmaris- Registry: BIOSOLVE-IV
  • Table 48: Magmaris Bioresorbable Magnesium Scaffold - BIOTRONIKS-Safety and Performance in de Novo Lesion of Native Coronary Arteries with Magmaris (BIOSOLVE)-IV Magmaris Swiss Satellite Registry
  • Table 49: Magmaris Bioresorbable Magnesium Scaffold - Coronary Artery Healing Process after Bioresorbable Scaffold in Patients with Non-ST-segment Elevation Myocardial Infarction (NSTEMI)
  • Table 50: Magmaris Bioresorbable Magnesium Scaffold - Magnesium-based Bioresorbable Scaffold and Vasomotor Function in Patients with Acute ST Segment Elevation Myocardial Infarction
  • Table 51: Magmaris Bioresorbable Magnesium Scaffold - Optical Coherence Guided Treatment of ST-segment Elevation Myocardial Infarction with the Drug-eluting Resorbable Magnesium Scaffold: The BEST- MAG Multicentre Study (Belgian ST-segment Elevation Myocardial Infarction Treatment with Resorbable Magnesium Scaffold)
  • Table 52: Magmaris Bioresorbable Magnesium Scaffold - Optical Coherence Tomography Evaluation of Bioabsorbable Vascular Scaffold Technique with Magmaris
  • Table 53: Magmaris Bioresorbable Magnesium Scaffold - Prospective Observational Registry of Patients with a Bioabsorbable Magnesium Stent Implant -MAGMARIS- in Usual Clinical Practice
  • Table 54: Magmaris Bioresorbable Magnesium Scaffold - Retrospective, Observational Register to Investigate the Procedural and Post Procedural Implantation of Bioabsorbable Magnesium Scaffolds MAGMARIS (MAGIC Registry)
  • Table 55: Magmaris Bioresorbable Magnesium Scaffold - Scaffold Implantation in Emilia-Romagna
  • Table 56: Magmaris Bioresorbable Magnesium Scaffold - 3rd Generation - BIOTRONIK - Safety and Clinical Performance of the - Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold System (DREAMS 3G) in the Treatment of Subjects with de Novo Lesions in Native Coronary Arteries
  • Table 57: Biotronik SE & Co KG Pipeline Products & Ongoing Clinical Trials Overview
  • Table 58: AMS-2 - Product Status
  • Table 59: AMS-2 - Product Description
  • Table 60: Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
  • Table 61: Fully Resorbable Drug-Eluting Scaffold System - Product Status
  • Table 62: Fully Resorbable Drug-Eluting Scaffold System - Product Description
  • Table 63: SYNERGY DES 4.5/5.0 - Product Status
  • Table 64: SYNERGY DES 4.5/5.0 - Product Description
  • Table 65: Boston Scientific Corp - Ongoing Clinical Trials Overview
  • Table 66: SYNERGY DES 4.5/5.0 - A U.S. Post-approval Study of the SYNERGY 4.50/5.00 mm Everolimus-eluting Platinum Chromium Coronary Stent System (Evolve 4.5/5.0)

List of Figures

  • Figure 1: Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development
  • Figure 2: Bioabsorbable Stents (BAS) - Pipeline Products by Territory
  • Figure 3: Bioabsorbable Stents (BAS) - Pipeline Products by Regulatory Path
  • Figure 4: Bioabsorbable Stents (BAS) - Pipeline Products by Estimated Approval Date
  • Figure 5: Bioabsorbable Stents (BAS) - Ongoing Clinical Trials
Back to Top